ATE350103T1 - Verwendung von nmda nr2b antagonist zur behandlung von depressionen. - Google Patents
Verwendung von nmda nr2b antagonist zur behandlung von depressionen.Info
- Publication number
- ATE350103T1 ATE350103T1 AT01308295T AT01308295T ATE350103T1 AT E350103 T1 ATE350103 T1 AT E350103T1 AT 01308295 T AT01308295 T AT 01308295T AT 01308295 T AT01308295 T AT 01308295T AT E350103 T1 ATE350103 T1 AT E350103T1
- Authority
- AT
- Austria
- Prior art keywords
- treating
- depression
- treat depression
- nr2b antagonist
- nmda nr2b
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title abstract 2
- 102000034527 Retinoid X Receptors Human genes 0.000 title abstract 2
- 108010038912 Retinoid X Receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 201000004569 Blindness Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010011878 Deafness Diseases 0.000 abstract 1
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 101710138657 Neurotoxin Proteins 0.000 abstract 1
- 208000005374 Poisoning Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 208000031889 Vascular Depression Diseases 0.000 abstract 1
- 208000001407 Vascular Headaches Diseases 0.000 abstract 1
- 230000010370 hearing loss Effects 0.000 abstract 1
- 231100000888 hearing loss Toxicity 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 239000002581 neurotoxin Substances 0.000 abstract 1
- 231100000618 neurotoxin Toxicity 0.000 abstract 1
- 231100000572 poisoning Toxicity 0.000 abstract 1
- 230000000607 poisoning effect Effects 0.000 abstract 1
- 230000004393 visual impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23777000P | 2000-10-02 | 2000-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE350103T1 true ATE350103T1 (de) | 2007-01-15 |
Family
ID=22895086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01308295T ATE350103T1 (de) | 2000-10-02 | 2001-09-28 | Verwendung von nmda nr2b antagonist zur behandlung von depressionen. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6958351B2 (de) |
| EP (1) | EP1199068B1 (de) |
| JP (1) | JP2002161052A (de) |
| KR (1) | KR100430539B1 (de) |
| AT (1) | ATE350103T1 (de) |
| AU (1) | AU7730401A (de) |
| CA (1) | CA2357929A1 (de) |
| DE (1) | DE60125681T2 (de) |
| ES (1) | ES2276750T3 (de) |
| HU (1) | HUP0104018A3 (de) |
| IL (1) | IL145584A0 (de) |
| NZ (1) | NZ514554A (de) |
| ZA (1) | ZA200107951B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
| US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| IL145584A0 (en) | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| CA2449249A1 (en) * | 2001-06-12 | 2002-12-19 | Merck & Co., Inc. | Nr2b receptor antagonists for the treatment or prevention of migraines |
| US6743921B2 (en) * | 2002-01-24 | 2004-06-01 | Dsm Catalytica Pharmaceuticals, Inc. | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds |
| US6855735B2 (en) * | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
| AU2003303040B2 (en) * | 2002-12-13 | 2009-04-23 | Warner-Lambert Company Llc | Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
| SE526255C2 (sv) * | 2003-03-14 | 2005-08-09 | Sandvik Intellectual Property | Verktyg och indexerbart skär för finsvarvning av rotationssymmetriska spår i arbetsstycken |
| KR20160029870A (ko) | 2008-04-21 | 2016-03-15 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| KR20110016891A (ko) * | 2008-05-09 | 2011-02-18 | 에모리 유니버시티 | 신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질 |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| US8648198B2 (en) | 2011-01-19 | 2014-02-11 | Cold Spring Harbor Laboratory | Phenylethanolamine-based NMDA receptor antagonists |
| EP2665474A1 (de) * | 2011-01-20 | 2013-11-27 | Merz Pharma GmbH & Co. KGaA | Neramexan zur behandlung oder vorbeugung von stressbedingtem tinnitus oder akutem hörverlust |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| IL234638A0 (en) * | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | NMDA receptor antagonists for the treatment of Gaucher disease |
| KR101705448B1 (ko) | 2015-05-18 | 2017-02-09 | 허동길 | 애완동물용 물통 |
| CA3027434C (en) | 2016-06-16 | 2025-02-04 | Cutispharma, Inc. | COMPOSITION AND METHOD FOR SUSPENDING A PROTON PUMP INHIBITOR |
| US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
| US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
| EP4255419A1 (de) * | 2020-12-04 | 2023-10-11 | Novartis AG | Dosierungsplan für einen nr2b-nmda-rezeptor nam zur behandlung von depression |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5710168A (en) * | 1991-10-23 | 1998-01-20 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as neuroprotective agents |
| DE69531154T2 (de) * | 1994-08-18 | 2004-04-08 | Pfizer Inc. | Neuroprotektive 3-(piperidinyl-1)-chroman-4,7-diol und 1-(4-hyphoxyphenyl)-2-(piperidinyl-1)-alkanolderivate |
| PL185603B1 (pl) * | 1995-08-11 | 2003-06-30 | Pfizer | Nowy trihydrat metanosulfonianu (1S,2S)-1-(4-hydroksyfenylo)-2-(4-hydroksy-4-fenylopiperydyn-1-ylo)-1-propanolu i środek farmaceutyczny |
| TW450807B (en) * | 1995-09-15 | 2001-08-21 | Pfizer | Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents |
| ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| ZA9610736B (en) * | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
| WO1997023202A1 (en) * | 1995-12-22 | 1997-07-03 | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON | Subtype-selective nmda receptor ligands and the use thereof |
| ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610741B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| EP0787493A1 (de) * | 1996-02-03 | 1997-08-06 | F. Hoffmann-La Roche Ag | Tetrahydroisochinolin-Derivate |
| KR200153170Y1 (ko) * | 1997-08-30 | 1999-08-02 | 정몽규 | 볼죠인트구조 |
| GB9804886D0 (en) * | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
| GB9804885D0 (en) * | 1998-03-06 | 1998-04-29 | Merck Sharp & Dohme | Therapeutic combination |
| PE20000728A1 (es) * | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| US20010007872A1 (en) * | 1998-10-01 | 2001-07-12 | Frank S. Menniti | Method of treating acute, chronic and/or neuropathic pain |
| IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
-
2001
- 2001-09-24 IL IL14558401A patent/IL145584A0/xx unknown
- 2001-09-27 ZA ZA200107951A patent/ZA200107951B/xx unknown
- 2001-09-28 CA CA002357929A patent/CA2357929A1/en not_active Abandoned
- 2001-09-28 AT AT01308295T patent/ATE350103T1/de not_active IP Right Cessation
- 2001-09-28 EP EP01308295A patent/EP1199068B1/de not_active Expired - Lifetime
- 2001-09-28 AU AU77304/01A patent/AU7730401A/en not_active Abandoned
- 2001-09-28 ES ES01308295T patent/ES2276750T3/es not_active Expired - Lifetime
- 2001-09-28 DE DE60125681T patent/DE60125681T2/de not_active Expired - Fee Related
- 2001-09-29 KR KR10-2001-0060916A patent/KR100430539B1/ko not_active Expired - Fee Related
- 2001-10-01 NZ NZ514554A patent/NZ514554A/en unknown
- 2001-10-01 HU HU0104018A patent/HUP0104018A3/hu unknown
- 2001-10-02 US US09/969,318 patent/US6958351B2/en not_active Expired - Fee Related
- 2001-10-02 JP JP2001306254A patent/JP2002161052A/ja active Pending
- 2001-10-02 US US09/969,317 patent/US7019016B2/en not_active Expired - Fee Related
-
2004
- 2004-04-09 US US10/821,526 patent/US20040192763A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HU0104018D0 (en) | 2001-12-28 |
| DE60125681D1 (de) | 2007-02-15 |
| US20040162312A1 (en) | 2004-08-19 |
| JP2002161052A (ja) | 2002-06-04 |
| ZA200107951B (en) | 2003-04-29 |
| US20040192763A1 (en) | 2004-09-30 |
| US6958351B2 (en) | 2005-10-25 |
| KR20020027203A (ko) | 2002-04-13 |
| NZ514554A (en) | 2004-10-29 |
| DE60125681T2 (de) | 2007-10-04 |
| US20020072538A1 (en) | 2002-06-13 |
| CA2357929A1 (en) | 2002-04-02 |
| HUP0104018A3 (en) | 2004-04-28 |
| US7019016B2 (en) | 2006-03-28 |
| EP1199068B1 (de) | 2007-01-03 |
| AU7730401A (en) | 2002-04-11 |
| KR100430539B1 (ko) | 2004-05-10 |
| ES2276750T3 (es) | 2007-07-01 |
| EP1199068A2 (de) | 2002-04-24 |
| EP1199068A3 (de) | 2003-06-18 |
| HUP0104018A2 (hu) | 2002-07-29 |
| IL145584A0 (en) | 2002-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE350103T1 (de) | Verwendung von nmda nr2b antagonist zur behandlung von depressionen. | |
| DE602006016760D1 (de) | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen | |
| GEP20094623B (en) | Heteroaromatic quinoline compounds and their use as pde10 inhibitors | |
| EP1481077A4 (de) | Mitotische kinesin-hemmer | |
| WO2005103041A3 (en) | Treatment of cns disorders using cns target modulators | |
| DE60045427D1 (de) | Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen | |
| EP1551812A4 (de) | Mitotische kinesinhemmer | |
| PT1355889E (pt) | Derivados diamina triazole substituidos como inibidores de cinase | |
| CY1112238T1 (el) | Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων | |
| ATE372341T1 (de) | Inhibitoren von mitotischem kinesin | |
| WO2006105516A3 (en) | Compositions and methods for diagnosing and treating neuropsychiatric disorders | |
| MX2009004791A (es) | Derivados de anilinopiperazina t metodos de uso de los mismos. | |
| ATE463247T1 (de) | Bupropion metaboliten zur behandlung von angstzuständen | |
| ATE528002T1 (de) | Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden | |
| WO2002032374A3 (en) | Methods for treating il-18 mediated disorders | |
| MX2009004785A (es) | Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa. | |
| ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
| DE602005015002D1 (de) | Methylendipiperidinderivate | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE457309T1 (de) | Modulatoren von peripheren 5-ht-rezeptoren | |
| WO2004047727A3 (en) | Compositions and methods for diagnosing and treating mood disorders | |
| ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
| ATE345818T1 (de) | S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen. | |
| JO2724B1 (en) | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors | |
| WO2007015170A8 (en) | Synapse-specific proteins in glomeruli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |